South Korea Continuous Bioprocessing Market Size, Share, and COVID-19 Impact Analysis, By Product (Instruments and Consumables & Reagents), By Application (Monoclonal Antibodies and Vaccines), By End Use (Pharmaceutical & Biotechnology Companies, CMOs & CROs, and Research & Academic Institutes), and South Korea Continuous Bioprocessing Market Insights, Industry Trend, Forecasts to 2035.

South Korea Continuous Bioprocessing Market Insights Forecasts to 2035

• The South Korea Continuous Bioprocessing Market Size Was Estimated at USD 7.98 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 20.08% from 2025 to 2035
• The South Korea Continuous Bioprocessing Market Size is Expected to Reach USD 59.74 Million by 2035

According to a research report published by Spherical Insights & Consulting, the South Korea Continuous Bioprocessing Market Size is anticipated to reach USD 59.74 Million by 2035, growing at a CAGR of 20.08% from 2025 to 2035. The increasing need for scalable and affordable biopharmaceutical manufacturing, especially for monoclonal antibodies, vaccines, and cell and gene therapies, is what propels the sector.

Market Overview

Continuous bioprocessing is an advanced manufacturing approach in the biopharmaceutical industry that enables uninterrupted production of biologics, such as vaccines and monoclonal antibodies, through integrated and automated systems. Unlike traditional batch processing, it offers significant benefits including higher productivity, improved product quality, reduced production time, and lower operational costs. The South Korean market presents strong opportunities driven by growing biologics demand, increasing R&D investments, and the expansion of biosimilar manufacturing. Government initiatives, such as funding for biotech innovation and infrastructure development, support this growth by encouraging adoption of cutting-edge technologies and partnerships between industry and academia. These efforts aim to strengthen South Korea’s position as a global leader in biopharmaceutical manufacturing and innovation.

Report Coverage

This research report categorizes the market for South Korea continuous bioprocessing market based on various segments and regions forecasts revenue growth, and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea continuous bioprocessing market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment South Korea continuous bioprocessing market.

Driving Factors

increasing biopharmaceutical demand, including mAbs, vaccines, cell and gene therapies, driven by an aging population and chronic diseases. Companies pursue cost efficiency, higher productivity, and smaller footprints via continuous systems. Technological advances AI, PAT sensors, single-use modules, continuous chromatography enable real-time control and scalability.

Restraining Factors

The high upfront capital required for specialized equipment, automation, and facility upgrades can deter smaller firms. Technical complexity and the need for skilled personnel challenge process development, scale up, and real time control. Regulatory uncertainties, including validation protocols and lack of standardized guidelines (e.g., ICH Q13), slow adoption due to compliance risks.

Market Segmentation

The South Korea continuous bioprocessing market share is classified into product, application, and end-use.

• The instruments segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea continuous bioprocessing market is segmented by product into instruments and consumables & reagents. Among these, the instruments segment held a significant share in 2024 and is expected to grow at a substantial CAGR during the forecast period. The increased adoption of advanced bioreactors, sensors, and control systems for real-time monitoring and process optimization. Rising demand for efficient, scalable biomanufacturing in pharmaceuticals and biologics drives growth, supported by technological innovation and investment in bioprocessing infrastructure.

• The monoclonal antibodies segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea continuous bioprocessing market is segmented by application into monoclonal antibodies and vaccines. Among these, the monoclonal antibodies segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The rising demand for targeted therapies in cancer, autoimmune, and infectious diseases. Continuous bioprocessing enhances production efficiency and consistency, supporting large-scale manufacturing. Increased R&D investment and strong biopharmaceutical pipeline.

• The pharmaceutical & biotechnology companies segment dominated share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea continuous bioprocessing market is segmented by end-use into pharmaceutical & biotechnology companies, CMOs & CROs, and research & academic institutes. Among thsese, the pharmaceutical & biotechnology companies segment dominated share in 2024 and is expected to grow at a significant CAGR during the forecast period. The strong focus on biologics development, process efficiency, and cost reduction. Increased investment in innovative therapeutics, robust manufacturing infrastructure, and demand for faster production timelines support adoption.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea continuous bioprocessing market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the companies' current news and developments, including product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Celltrion Inc. 
• Samsung Biologics
• GC Biopharma (Green Cross Corporation) 
• Hanmi Pharmaceutical Co., Ltd. 
• yeasitech.com
• LG Chem Life Sciences
• CJ BIO
• Bio Design Lab 
• NuriBio
• SeaWith
• LegoChem (LigaChem Biosciences) 
• Genofocus, Inc.
• ImmuneMed Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea continuous bioprocessing market based on the below-mentioned segments:

South Korea Continuous Bioprocessing Market, By Product

• Instruments
• Consumables & Reagents

South Korea Continuous Bioprocessing Market, By Application

• Monoclonal Antibodies
• Vaccines

South Korea Continuous Bioprocessing Market, By End-use

• Pharmaceutical & Biotechnology Companies
• CMOs & CROs
• Research & Academic Institutes